1. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (September 2015) Authors: Van Cutsem, E.; Obermannova, R.; Bodoky, G.; Prausová, J.; García-Carbonero, R.; Ciuleanu, T.; Alfonso, P Garcia; Portnoy, D.; Cohn, A.; Yamazaki, K.; Clingan, P; Yoshino, T.; Polikoff, J.; Lonardi, S.; Macarulla, T.; Yang, L.; Nasroulah, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. (September 2015) Authors: Cohn, A. Lee; Yoshino, T.; Obermannova, R.; Bodoky, G.; Prausova, J.; Garcia-Carbonero, R.; Ciuleanu, T. Eliade; Garcia-Alfonso, P.; Portnoy, D.C.; Van Cutsem, E.; Yamazaki, K.; Clingan, P.R.; Polikoff, J.; Lonardi, S.; Gao, L.; Yang, L.; Chang, S.C.; Ferry, D.; Nasroulah, F.; Tabernero, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW). (September 2015) Authors: Chau, I.; Fuchs, C.; Muro, K.; Tomasek, J.; Van Cutsem, E.; Cho, J.Y.; Oh, S.C.; Safran, H.; Bodoky, G.; Shimada, Y.; Dumitru, F.; Passalacqua, R.; Ohtsu, A.; Hsu, Y.; Liepa, A.; Chandrawansa, K.; Emig, M.; Ferry, D.; Wilke, H.; Al-Batran, S.E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. (March 2020) Authors: Van Cutsem, E.; Muro, K.; Cunningham, D.; Bodoky, G.; Sobrero, A.; Cascinu, S.; Ajani, J.; Oh, S.C.; Al-Batran, S.E.; Wainberg, Z.A.; Wijayawardana, S.R.; Melemed, S.; Ferry, D.; Hozak, R.R.; Ohtsu, A. Journal: European journal of cancer Issue: Volume 127(2020) Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Medical Oncology Workload in Europe: One Continent, Several Worlds. Issue 1 (January 2020) Authors: Seruga, B.; Sullivan, R.; Fundytus, A.; Hopman, W.M.; Ocana, A.; Joffe, J.; Bodoky, G.; Le Tourneau, C.; Vanderpuye, V.; Lopes, G.; Hammad, N.; Sengar, M.; Brundage, M.D.; Booth, C.M. Journal: Clinical oncology Issue: Volume 32:Issue 1(2020) Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗